Hutchens Investment Management Inc Buys Shares of 1,250 Chemed Co. (CHE)

Hutchens Investment Management Inc bought a new position in shares of Chemed Co. (NYSE:CHE) during the fourth quarter, HoldingsChannel reports. The firm bought 1,250 shares of the company’s stock, valued at approximately $303,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Chemed by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock worth $374,435,000 after buying an additional 34,938 shares in the last quarter. State Street Corp lifted its holdings in Chemed by 1.8% during the 2nd quarter. State Street Corp now owns 453,605 shares of the company’s stock worth $92,782,000 after buying an additional 8,238 shares in the last quarter. Investec Asset Management LTD lifted its holdings in Chemed by 1.8% during the 3rd quarter. Investec Asset Management LTD now owns 323,231 shares of the company’s stock worth $65,309,000 after buying an additional 5,717 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Chemed by 39.7% during the 2nd quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock worth $43,926,000 after buying an additional 61,056 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Chemed by 111.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock worth $36,125,000 after buying an additional 96,237 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

In related news, Director Donald E. Saunders sold 500 shares of Chemed stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $227.75, for a total transaction of $113,875.00. Following the sale, the director now directly owns 10,298 shares in the company, valued at approximately $2,345,369.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Patrick Williams sold 11,000 shares of Chemed stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the sale, the insider now owns 74,857 shares in the company, valued at $18,061,496.96. The disclosure for this sale can be found here. Insiders sold a total of 45,679 shares of company stock worth $10,628,959 over the last 90 days. Company insiders own 4.90% of the company’s stock.

Shares of Chemed Co. (NYSE:CHE) traded up $3.51 on Wednesday, hitting $260.05. 140,100 shares of the stock were exchanged, compared to its average volume of 102,583. Chemed Co. has a fifty-two week low of $161.18 and a fifty-two week high of $261.91. The firm has a market cap of $4,100.00, a price-to-earnings ratio of 57.92, a price-to-earnings-growth ratio of 2.87 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.15. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The business had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. During the same period last year, the business earned $1.73 EPS. The company’s revenue was up 6.3% on a year-over-year basis. equities research analysts expect that Chemed Co. will post 4.73 EPS for the current year.

CHE has been the topic of a number of analyst reports. KeyCorp restated a “hold” rating on shares of Chemed in a report on Friday, October 27th. Royal Bank of Canada restated a “hold” rating and issued a $209.00 price objective on shares of Chemed in a report on Tuesday, October 3rd. Zacks Investment Research lowered shares of Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $236.00.

COPYRIGHT VIOLATION WARNING: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/01/10/hutchens-investment-management-inc-buys-shares-of-1250-chemed-co-che.html.

Chemed Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply